aspirin has been researched along with Leg Ulcer in 25 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Leg Ulcer: Ulceration of the skin and underlying structures of the lower extremity. About 90% of the cases are due to venous insufficiency (VARICOSE ULCER), 5% to arterial disease, and the remaining 5% to other causes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to determine the effect of low-dose aspirin on venous leg ulcer healing when used in addition to compression." | 9.22 | Low-dose aspirin as an adjuvant treatment for venous leg ulceration: study protocol for a randomized controlled trial (Aspirin4VLU). ( Bullen, C; Jull, A; Kerse, N; Parag, V; Wadham, A; Waters, J, 2016) |
| "Four patients with livedo vasculitis were started on a regimen of beraprost sodium (120 micrograms daily)." | 9.08 | Successful treatment of livedo vasculitis with beraprost sodium: a possible mechanism of thrombomodulin upregulation. ( Shirasaki, F; Takata, M; Takehara, K; Tsutsui, K, 1996) |
| "The aim of this study was to determine the effect of low-dose aspirin on venous leg ulcer healing when used in addition to compression." | 5.22 | Low-dose aspirin as an adjuvant treatment for venous leg ulceration: study protocol for a randomized controlled trial (Aspirin4VLU). ( Bullen, C; Jull, A; Kerse, N; Parag, V; Wadham, A; Waters, J, 2016) |
| "Four patients with livedo vasculitis were started on a regimen of beraprost sodium (120 micrograms daily)." | 5.08 | Successful treatment of livedo vasculitis with beraprost sodium: a possible mechanism of thrombomodulin upregulation. ( Shirasaki, F; Takata, M; Takehara, K; Tsutsui, K, 1996) |
| " We conducted 31 semi-structured telephone interviews of patients who participated in the Aspirin in Venous Leg Ulcer (ASPiVLU) randomised controlled trail (RCT) or ASPiVLU cohort study." | 3.96 | Rationale for participation in venous leg ulcer clinical research: Patient interview study. ( Richards, C; Team, V; Turnour, L; Weller, CD, 2020) |
| "Genetically, Klinefelter's syndrome is characterized by a super-numerary chromosome X in male subjects presenting with clinical and biochemical hypoandrogenism and relative hyperoestrogenism." | 2.38 | [Klinefelter's syndrome and leg ulcers: role of blood coagulation disorders]. ( Berbis, P; Bonerandi, JJ; Hesse, S; Juhan-Vague, I; Privat, Y, 1992) |
| "However, in sickle cell anemia, does the obligate period of flap ischemia inherent in free-tissue transfer inevitably doom a flap to failure? We present our multidisciplinary experience over 55 months with five free flaps in four homozygous sickle cell anemia patients 21 to 38 years old who had chronic nonhealing leg ulcerations." | 1.29 | Lower limb salvage by microvascular free-tissue transfer in patients with homozygous sickle cell disease. ( Koshy, M; Marschall, M; Schuler, J; Weinzweig, N, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (20.00) | 18.7374 |
| 1990's | 8 (32.00) | 18.2507 |
| 2000's | 3 (12.00) | 29.6817 |
| 2010's | 7 (28.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weller, CD | 1 |
| Richards, C | 1 |
| Turnour, L | 1 |
| Team, V | 1 |
| Razmi T, M | 1 |
| Jindal, AK | 1 |
| Arora, K | 1 |
| Joshi, V | 1 |
| Suri, D | 1 |
| De, D | 1 |
| Jull, A | 2 |
| Wadham, A | 2 |
| Bullen, C | 2 |
| Parag, V | 2 |
| Kerse, N | 2 |
| Waters, J | 2 |
| Criado, PR | 1 |
| Alavi, A | 1 |
| Halpern, I | 1 |
| Sotto, MN | 1 |
| Kirsner, RS | 1 |
| Castillo-Martínez, C | 1 |
| Moncada, B | 1 |
| Valdés-Rodríguez, R | 1 |
| González, FJ | 1 |
| Lewerenz, V | 1 |
| Burchardt, T | 1 |
| Büchau, A | 1 |
| Ruzicka, T | 1 |
| Megahed, M | 1 |
| Barlas, S | 1 |
| Tansel, T | 1 |
| Reilly, JT | 1 |
| Weinzweig, N | 1 |
| Schuler, J | 1 |
| Marschall, M | 1 |
| Koshy, M | 1 |
| Newton, W | 1 |
| Bühler-Singer, S | 1 |
| von Hintzenstern, J | 1 |
| Fartasch, M | 1 |
| Hornstein, OP | 1 |
| Tsutsui, K | 1 |
| Shirasaki, F | 1 |
| Takata, M | 1 |
| Takehara, K | 1 |
| Goodfield, M | 1 |
| Walker, M | 1 |
| Hulme, TA | 1 |
| Rippon, MG | 1 |
| Walmsley, RS | 1 |
| Gunnigle, S | 1 |
| Lewin, M | 1 |
| Winsey, S | 1 |
| Hafner, J | 1 |
| Hesse, S | 1 |
| Berbis, P | 1 |
| Juhan-Vague, I | 1 |
| Bonerandi, JJ | 1 |
| Privat, Y | 1 |
| Heng, MC | 1 |
| Song, MK | 1 |
| Heng, MK | 1 |
| Grossman, JA | 1 |
| Barrall, DT | 1 |
| Dennison, A | 1 |
| Lally, EV | 1 |
| Huntsman, RG | 1 |
| Lehmann, H | 1 |
| van der Molen, HR | 1 |
| Töth, LM | 1 |
| Galambos, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Low Dose Aspirin for Venous Leg Ulcers: a Randomised Trial[NCT02158806] | Phase 3 | 251 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in estimated ulcer area from baseline to 24 weeks (NCT02158806)
Timeframe: Baseline, 24 weeks
| Intervention | square centimetres (Mean) |
|---|---|
| Aspirin | 4.1 |
| Placebo | 4.8 |
Mean difference in change measured by EuroQol 5D (EQ5D 3L) from baseline to 24 weeks. Crude health state scores for each group are not shown (health state is scored 0 to 100 at baseline and 24 weeks); higher mean differences in change from baseline to 24 weeks within groups indicate greater change on health state for that group. (NCT02158806)
Timeframe: Baseline, 24 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Aspirin | 7.4 |
| Placebo | 4.0 |
Adherence to study medication as measured by pill counts (agreement between expected number of tablets remaining after healing and days to healing) (NCT02158806)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 92 |
| Placebo | 92 |
Number of participants in each arm with completely healed reference ulcers at 24 weeks (NCT02158806)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 88 |
| Placebo | 101 |
Time to event (complete healing defined as intact skin with absence of scab) (NCT02158806)
Timeframe: 24 weeks
| Intervention | days (Median) |
|---|---|
| Aspirin | 77 |
| Placebo | 69 |
Mean difference in change in Charing Cross Venous Ulcer Questionnaire (CXVUQ)) from baseline to 24 weeks. Crude subscale scores for each group are not shown (each crude subscale is scored 0 to 100 at baseline and 24 weeks); higher mean differences in change from baseline to 24 weeks within groups indicate greater change on the subscales for that group. (NCT02158806)
Timeframe: 24 weeks
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Social function | Domestic activities | Cosmesis | Emotional status | Overall | |
| Aspirin | -6.2 | -6.6 | -6.1 | -9.4 | -7.3 |
| Placebo | -4.7 | -5.2 | -4.9 | -6.5 | -5.5 |
Mean difference in change in Short Form 36 (SF36) from baseline to 24 weeks. Crude subscale scores for each group are not shown (each crude subscale is scored 0 to 100 at baseline and 24 weeks); higher mean differences in change from baseline to 24 weeks within groups indicate greater change on the subscales for that group. (NCT02158806)
Timeframe: Baseline, 24 weeks
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Physical Functioning | Role Physical | Bodily Pain | General Health | Vitality | Social Functioning | Role Emotional | Mental Health | |
| Aspirin | 5.0 | 11.7 | 11.4 | -1.1 | 3.9 | 5.8 | 10.5 | -1.2 |
| Placebo | 3.8 | 10.3 | 9.0 | -0.8 | -0.3 | 4.9 | 6.8 | 1.2 |
3 reviews available for aspirin and Leg Ulcer
| Article | Year |
|---|---|
Optimal management of chronic leg ulcers in the elderly.
Topics: Administration, Oral; Aged; Aging; Arterial Occlusive Diseases; Aspirin; Bandages; Combined Modality | 1997 |
Management of arterial leg ulcers and of combined (mixed) venous-arterial leg ulcers.
Topics: Alprostadil; Arterial Occlusive Diseases; Aspirin; Bandages; Electric Stimulation Therapy; Exercise | 1999 |
[Klinefelter's syndrome and leg ulcers: role of blood coagulation disorders].
Topics: Adult; Aspirin; Blood Coagulation Disorders; Gonadal Steroid Hormones; Humans; Klinefelter Syndrome; | 1992 |
3 trials available for aspirin and Leg Ulcer
| Article | Year |
|---|---|
Low dose aspirin as adjuvant treatment for venous leg ulceration: pragmatic, randomised, double blind, placebo controlled trial (Aspirin4VLU).
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Aspirin; Dose-Response Relationship, Drug; Double-Blind Method | 2017 |
Low-dose aspirin as an adjuvant treatment for venous leg ulceration: study protocol for a randomized controlled trial (Aspirin4VLU).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Compression Bandages; Cost-Benefit Analysis; Dose-Response | 2016 |
Successful treatment of livedo vasculitis with beraprost sodium: a possible mechanism of thrombomodulin upregulation.
Topics: Adolescent; Adult; Aged; Aspirin; Child; Drug Therapy, Combination; Epidermis; Epoprostenol; Female; | 1996 |
19 other studies available for aspirin and Leg Ulcer
| Article | Year |
|---|---|
Rationale for participation in venous leg ulcer clinical research: Patient interview study.
Topics: Aged; Aged, 80 and over; Aspirin; Female; Humans; Leg Ulcer; Male; Middle Aged; Motivation; Patient | 2020 |
Refractory leg ulcers in prolidase deficiency with antiphospholipid antibody positivity responding to aspirin-hydroxychloroquine-vitamin C combination therapy.
Topics: Antibodies, Antiphospholipid; Ascorbic Acid; Aspirin; Humans; Hydroxychloroquine; Leg Ulcer; Prolida | 2020 |
Unilateral livedoid vasculopathy associated with involutional phase of cutaneous infantile hemangioma: the connection to coagulation disorders.
Topics: Adolescent; Aspirin; Biopsy; Blood Coagulation Disorders; Blood Coagulation Tests; Diagnosis, Differ | 2013 |
Livedoid vasculopathy (LV) associated with sticky platelets syndrome type 3 (SPS type 3) and enhanced activity of plasminogen activator inhibitor (PAI-1) anomalies.
Topics: Aspirin; Blood Platelets; Child; Female; Humans; Leg Ulcer; Plasminogen Activator Inhibitor 1; Plate | 2014 |
Wound ulcer recruits needed.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Humans; Leg Ulcer; Middle | 2015 |
Aspirin can aid bandage as the best treatment for leg ulcers.
Topics: Aspirin; Compression Bandages; Humans; Leg Ulcer; Varicose Ulcer; Wound Healing | 2016 |
Venous leg ulcer study needs more participants.
Topics: Aspirin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Leg Ulcer; Vascular Dis | 2016 |
[Livedoid vasculopathy with heterozygous factor V Leiden mutation and sticky platelet syndrome].
Topics: Activated Protein C Resistance; Anticoagulants; Aspirin; Blood Platelets; Factor V; Fibrinolytic Age | 2004 |
Antiphospholipid syndrome in a child: an insight into the pathology, identification, and means of cure.
Topics: Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Arterial Occlusive Diseases; | 2004 |
Practical approach to treating essential thrombocythaemia: case studies.
Topics: Adult; Aspirin; Disease Management; Female; Humans; Hydroxyurea; Interferon-alpha; Leg Ulcer; Male; | 2007 |
Lower limb salvage by microvascular free-tissue transfer in patients with homozygous sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Anti-Bacterial Agents; Aspirin; Dextrans; Exchange Transfusion, Whole Bl | 1995 |
Does aspirin heal leg ulcers?
Topics: Administration, Oral; Aspirin; Bandages; Chronic Disease; Combined Modality Therapy; Double-Blind Me | 1995 |
[Anticardiolipin syndrome with only skin involvement].
Topics: Adult; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Arm; Aspirin; Azathioprine; Combined | 1994 |
In vitro model(s) for the percutaneous delivery of active tissue repair agents.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents; Aspirin; Bridged Bicyclo Compounds, He | 1997 |
Healing of necrobiotic ulcers with antiplatelet therapy. Correlation with plasma thromboxane levels.
Topics: Adult; Aged; Aspirin; Blood Platelets; Dipyridamole; Drug Therapy, Combination; Humans; Leg Ulcer; M | 1989 |
Successful combined medical and surgical treatment of a lower extremity sclerodermal ulcer.
Topics: Aged; Aspirin; Combined Modality Therapy; Debridement; Dipyridamole; Etidronic Acid; Female; Humans; | 1988 |
Treatment of sickle-cell disease.
Topics: Anemia, Sickle Cell; Anesthesia; Anticoagulants; Aspirin; Bicarbonates; Blood; Blood Flow Velocity; | 1974 |
Clinical and therapeutical problems concerning postthrombotic indurations.
Topics: Ascorbic Acid; Aspirin; Atrophy; Auscultation; Cellulitis; Drug Combinations; Edema; Humans; Leg Ulc | 1972 |
[Clinical therapy of leg ulcer and thrombophlebitis using Colfarit].
Topics: Aspirin; Humans; Leg; Leg Ulcer; Thrombophlebitis | 1973 |